Cochrane Review Finds Alzheimer's Anti-Amyloid Drugs Have 'Trivial' Clinical Impact
An extensive Cochrane Review has concluded that drugs hailed as a gamechanger for Alzheimer's disease make no noticeable difference to patients, with effects described as trivial. The analysis pooled data from 17 clinical trials involving over 20,000 participants with mild cognitive impairment or mild dementia, assessing seven anti-amyloid drugs over typical 18-month periods.
No Meaningful Effect on Cognitive Decline
The review found that the effects of these drugs on cognition and dementia severity were trivial, with improvements in functional ability deemed small at best. According to Edo Richard, a co-author and professor of neurology at Radboud University medical centre in the Netherlands, there is no clinically meaningful effect on cognitive decline or dementia severity. He noted that the drugs caused more swelling and bleeding in the brain than placebos and were burdensome due to frequent clinic visits for intravenous infusions and MRI scans.
Debate Over Pooling of Data
The Cochrane Review used gold standard methods to assess published clinical trials but faced criticism for combining results from older, failed drugs with newer, more effective medicines. Charles Marshall, professor of clinical neurology at Queen Mary, University of London, argued that pooling effective and ineffective treatments leads to a small or absent average treatment effect. In contrast, Dr Susan Kohlhaas at Alzheimer's Research UK stated that the study paints an entire class of drugs with the same brush, despite differences in how anti-amyloid treatments act, and noted that only two of the 17 studies focused on approved drugs like lecanemab and donanemab.
Regulatory and Economic Implications
Anti-amyloid drugs, including lecanemab by Eisai and donanemab by Eli Lilly, have been approved by medical regulators worldwide but face barriers in public health services. In the UK, the National Institute for Health and Care Excellence (Nice) deemed the cost to the NHS unjustified despite the drugs slowing the disease by four to six months, though it is revisiting the decision after manufacturer appeals. Robert Howard, professor of old age psychiatry at UCL, expressed doubts about whether these drugs truly alter Alzheimer's course, emphasizing that even the best-performing ones lack clinically meaningful impact.
Future Directions in Alzheimer's Research
The review concludes that researchers should explore new ways to treat Alzheimer's, as anti-amyloid drugs are not the whole answer. The analysis highlights the need for a wider range of biological targets, with ongoing research moving beyond amyloid-focused approaches. This verdict challenges the initial optimism around these drugs and underscores the complexity of developing effective treatments for neurodegenerative diseases.
